

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 31, 2007

Signature: 

(Lenay Rogers)

Patent

Docket No. 529282002600

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Trent Martin WOODRUFF et al.

Serial No.: 10/594,358

Filing Date: (Int'l) March 21, 2005

For: TREATMENT OF NEUROLOGICAL  
CONDITIONS USING COMPLEMENT  
C5A RECEPTOR MODULATORS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

The document numbers 1, 3, 4, 9, 10, and 23 listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on May 5, 2005, directed to a counterpart international or foreign application and have not been previously cited.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_ is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_ is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;  
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 529282002600.

Dated: August 31, 2007

Respectfully submitted,

By /Kate H. Murashige/  
Kate H. Murashige  
Registration No.: 29,959  
MORRISON & FOERSTER LLP  
12531 High Bluff Drive, Suite 100  
San Diego, California 92130-2040  
(858) 720-5112

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/594,358
				Filing Date	(Int'l) March 21, 2005
				First Named Inventor	Trent Martin WOODRUFF
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	529282002600

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	1.	EP-1 308 438	05/2003			
	2.	WO-99/00406	01/1999			
	3.	WO-03/033528	04/2003			
	4.	WO-05/007087	01/2005			

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	5.	BLUM et al., Neuropharmacol. and Neurotoxicol. (2001) 12:1769-1772	
	6.	BLUM et al., J. Neuroscience (2002) 22:9122-9133	
	7.	FAIRLIE et al., Curr. Med. Chem. (1998) 5:29-62	
	8.	FAIRLIE et al., Curr. Med. Chem. (1995) 2:654-686	
	9.	FARKAS et al., J. Immunol. (2003) 170 (11):5764-5771	
	10.	GASQUE et al., Immunopharmacology (2000) 49:171-186	
	11.	GAVRIELI et al., J. Cell. Biol. (1992) 119:493-501	
	12.	GERARD and GERARD, Ann. Rev. Immunol. (1994) 12:775-808	
	13.	HOWLAND et al., PNAS USA (2002) 99:1604-1609	
	14.	International Search report for PCT/AU2005/000403, mailed on May 5, 2005, 3 pages	
	15.	JULIAN et al., Endocrinology (1992) 130:79-87	
	16.	KATSUNO et al., Nat. Med. (2003) 9:768-773	
	17.	KLEMENT et al., Cell (1998) 95:41-53	
	18.	KONTEATIS et al., J. Immunol. (1994) 153:4200-4204	
	19.	LA SPADA et al., Nature (1991) 352:77-79	
	20.	MANGIARINI et al., Cell (1996) 87:493-506	
	21.	MCMANAMNY et al., Human Molecular Genetics (2002) 11(18):2103	
	22.	NISHINO et al., Journal of Neurotrauma (2000) 17:251-260	
	23.	OSAKA et al., Neuroscience (1999) 88(4):1073-1082	
	24.	PALFI et al., J. Neuroscience (1996) 16:3019-3025	
	25.	RALPH et al., Nature Medicine (2005) 11(4):429-433	
	26.	RAOUL et al., Nature Medicine (2005) 11(4):423-428	
Examiner Signature			Date Considered

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/594,358
				Filing Date	(Int'l) March 21, 2005
				First Named Inventor	Trent Martin WOODRUFF
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	529282002600

27.	ROSS, Neuron (2002) 35:819-822	
28.	ROTHERMEL et al., Scand. J. Immunol. (2000) 52(4):401-410	
29.	SANDERSON et al., J. Med. Chem. (1995) 38:3669-3675	
30.	SHIMANO et al., Obesity Research (1995) 3:779S-784S	
31.	SIMIC et al., J. Neuropathol. Exp. Neurol. (2000) 59:398-407	
32.	SINGHRAO et al., Experimental Neurology (1999) 159:362-376	
33.	STRAUSS and MORTON, Amer. J. Medical Genetics (Semin. Med. Genet.) (2003) 121C:53-70	
34.	TYNDALL and FAIRLIE, Curr. Med. Chem. (2001) 8:893-907	
35.	WANG et al., Neuroreport (1999) 10(12):2435-2438	
36.	ZOGHBI and ORR, Ann. Rev. Neurosci. (2000) 23:217-247	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--